Peter: I hate people with memories! Where did you drag that old message up from? <Grin>
I talked with Paul Boni at Genesis Merchant ten minutes after the conference call. I thought his speculation voiced during the conference that there might actually be efficacy shown in the later analysis (in about 3 1/2 months) was not very professional. Sure I'd like to think that might happen, but it's really putting a spin on this event that is unwarrantedly optimistic, especially for someone calling themselves an analyst. I like Paul, and for instance, agree with his brave long-term support of antisense and Isis Pharmaceutical, one of my holdings, but I've noticed he may also take too rosy a view of situations....
Personally, I think it's too late to sell. Paul says the TBI market is almost as large as the stroke market, and reasons that if you cut his target price of 35 for CNSI in half (based on an original presumption of Cerestat approval for both stoke and TBI), then assume Cerestat is instead only approved for TBI, you've still got a 17 dollar stock now selling for $4.00! Since the company has $3.00 in cash, you're merely paying a point for all their research, patents, etc. Looks like a HOLD to me!
Stay in touch! Here's hoping your memory ages rapidly! <G> |
